热点栏目 自选股 数据中心 行情中心 资金流向 模拟交易

客户端

　　锦欣生殖（01951）发布截至2024年12月31日止年度业绩，该集团期内取得28.12亿元（人民币，下同），同比增加0.81%；公司拥有人应占利润2.83亿元，同比减少17.88%；每股基本盈利0.11元。

　　公告称，尽管2024年取卵周期总数较2023年下降约6.3%，但有关下降的影响被（i）由于分娩数量同比增长约5.5%，妇产科服务需求增加；（ii）由于四川锦欣西囡医院（毕升院区）及深圳的VIP渗透率分别同比增长约2.0%及2.8%，每个取卵周期的平均支出增加所抵销；及（iii）海外业务取卵周期数同比增长约18.2%。因此，集团的收入于2024年大致保持稳定。

海量资讯、精准解读，尽在新浪财经APP

责任编辑：卢昱君

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.